Drugmaker Shire is hoping to buy Baxalta, a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.
The London-listed group went public with its approach after the US firm turned it down.
Shire said its unsolicited offer of 0.1687 Shire American depositary receipts per share valued each Baxalta share at $45.23. Shares in Baxalta jumped 19 per cent to $39.50 in pre-market trading.
The Illinois-based firm, which has a staff of around 16,000, develops biotech treatments for rare blood conditions, cancers and immune system disorders. It had revenue of $6 billion in 2014.
The move is the latest in a wave of mergers and acquisitions in the healthcare sector since the start of 2014, stretching from large drugmakers buying up smaller rivals to consolidation among makers of generic medicines and tie-ups between insurers.
Shire's all-share offer, which represents a premium of 36 per cent over Baxalta's stock price on August 3, would give the US firm's shareholders about 37 per cent of the combined group.
Shire chief executive Flemming Ornskov said he had gone public with its plan, which it first proposed privately last month, after Baxalta's board declined to engage in substantive discussions.
"We believe the proposed combination of Shire and Baxalta would be strategically and financially attractive for both of our companies, accelerating our respective growth ambitions and creating the leading global biotech company in rare diseases," he said.
"It is our strong preference to immediately enter into a negotiated transaction to explore the full potential of the proposed combination and finalise the terms of an agreement."
Shares in Shire were down around 4 percent on the news.
Shire, which has its headquarters in Ireland, has a long history of acquisitions and only on Monday agreed to buy private eye drug company Foresight Biotherapeutics for $300 million.
Other notable deals include buying New River Pharmaceuticals for $2.3 billion in 2007, Viropharma in 2013 for $4.2 billion and NPS Pharma for $5.2 billion earlier this year.
Last year Shire itself was the target of a failed $50 billion takeover attempt by AbbVie, since when its shares have risen to a premium to AbbVie's offer on growing optimism for its line-up of high-priced niche medicines.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here